Moderna beats fourth-quarter revenue estimates

Moderna reported fourth-quarter revenue above Wall Street estimates on Friday, banking on better-than-expected sales of its COVID-19 vaccine in the U.S.

Reuters • Feb 13, 2026

Moderna Just Crushed Estimates While Everyone Was Looking the Other Way

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street's muted expectations, delivering revenue of $678 million against estimates of $663 million and a loss of $2.11 per share compared to the expected loss of $2.64.

24/7 Wall Street • Feb 13, 2026

Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms

Moderna Inc. (NASDAQ: MRNA) on Friday reported a fourth-quarter loss of $2.11, beating the expected loss of $2.59, lower than a loss of $2.91 a year ago.

Benzinga • Feb 13, 2026

Moderna Pops On Fourth-Quarter Report, But Can It Overcome Recent FDA Setbacks?

Moderna stock popped Friday after the company reported better-than-expected fourth-quarter sales and reiterated its 2026 outlook.

Investors Business Daily • Feb 13, 2026

Moderna shares pop on strong guidance, smaller-than-expected loss

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported fourth quarter 2025 results that exceeded Wall Street expectations, sending its shares up about 11% on Friday. The company posted a net loss of $2.11 per share on revenue of $678 million, compared with analysts' consensus of a $2.60 loss on revenue near $660 million.

Proactive Investors • Feb 13, 2026

Moderna Narrows Loss, Reiterates 10% Revenue Growth Target

Moderna said it continues to target 10% revenue growth this year, as the company's fourth-quarter loss narrowed from a year earlier.

WSJ • Feb 13, 2026

Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend

MRNA is showing early signs of a new bull trend after earnings beat expectations, with technical support holding and upside targets forming above key resistance levels.

FXEmpire • Feb 13, 2026

Moderna Reports a Narrower-Than-Expected Loss. The Stock Falls After Earnings.

Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.

Barrons • Feb 13, 2026

Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript

Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 13, 2026

Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11) Reports full-year revenue of $1.9 billion, GAAP net loss of $(2.8) billion and GAAP diluted EPS of $(7.26) Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026 Announces influenza vaccine filing accepted for regulatory review in the EU, Canada and Australia; Company received Refusal-to-File letter from U.S. FDA and has requested Type A meeting to understand path forward Announces Norovirus Phase 3 trial fully enrolled with a data readout expected in 2026 Announces full enrollment of Phase 2 intismeran autogene trial in muscle invasive bladder cancer CAMBRIDGE, MA / ACCESS Newswire / February 13, 2026 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter of 2025. "In 2025, we sharpened our commercial execution, launched our third product and brought online three international manufacturing sites, while advancing our mRNA pipeline.

Accesswire • Feb 13, 2026